Marie L Chardon1, Kimberly L Klages1, Naomi E Joffe2,3,4, Ahna L H Pai5,6,7. 1. Division of Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, USA. 2. Division of Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, USA. 3. Patient and Family Wellness Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, USA. 4. Department of Pediatrics, University of Cincinnati College of Medicine, USA. 5. Division of Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, USA. 6. Patient and Family Wellness Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, USA. 7. Department of Pediatrics , University of Cincinnati College of Medicine, USA.
Abstract
OBJECTIVE: Medications are critical for reducing morbidity and mortality risk in pediatric hematopoietic stem cell transplant (HCT). Nonetheless, medication adherence is suboptimal in this population. Identifying and managing barriers to medication management (i.e., medication barriers) is a key component of supporting medication adherence. However, understanding how medication barriers uniquely impact the pediatric HCT population and which barriers characterize each treatment stage remain unclear. Therefore, this study examined caregiver-perceived medication barriers over the course of pediatric HCT. METHODS: Semi-structured qualitative interviews and demographic questionnaires were completed by 29 caregivers of children (≤12 years) who had received an HCT in the past 24 months and were either still admitted to, or had been discharged from, the hospital. RESULTS: Grounded methodology revealed 21 qualitative themes grouped into 6 hierarchical categories. Findings reflected barriers to be present across HCT treatment but to differ based on treatment stage with only child medication refusal being a consistent barrier across all stages. Barriers were particularly prevalent after hospital discharge post-HCT when caregivers assumed full responsibility for medication management. In addition, families approaching hospital discharge often lacked insight about these post-discharge barriers such that they did not report anticipating the range of barriers described by caregivers who had already been discharged from the hospital and taken on full responsibility for medication management. CONCLUSIONS: Findings support the benefit of medication barrier assessment across HCT treatment. These results suggest that families may benefit from intervention to address the specific barriers they experience around medication adherence especially during the post-HCT outpatient period.
OBJECTIVE: Medications are critical for reducing morbidity and mortality risk in pediatric hematopoietic stem cell transplant (HCT). Nonetheless, medication adherence is suboptimal in this population. Identifying and managing barriers to medication management (i.e., medication barriers) is a key component of supporting medication adherence. However, understanding how medication barriers uniquely impact the pediatric HCT population and which barriers characterize each treatment stage remain unclear. Therefore, this study examined caregiver-perceived medication barriers over the course of pediatric HCT. METHODS: Semi-structured qualitative interviews and demographic questionnaires were completed by 29 caregivers of children (≤12 years) who had received an HCT in the past 24 months and were either still admitted to, or had been discharged from, the hospital. RESULTS: Grounded methodology revealed 21 qualitative themes grouped into 6 hierarchical categories. Findings reflected barriers to be present across HCT treatment but to differ based on treatment stage with only child medication refusal being a consistent barrier across all stages. Barriers were particularly prevalent after hospital discharge post-HCT when caregivers assumed full responsibility for medication management. In addition, families approaching hospital discharge often lacked insight about these post-discharge barriers such that they did not report anticipating the range of barriers described by caregivers who had already been discharged from the hospital and taken on full responsibility for medication management. CONCLUSIONS: Findings support the benefit of medication barrier assessment across HCT treatment. These results suggest that families may benefit from intervention to address the specific barriers they experience around medication adherence especially during the post-HCT outpatient period.
Authors: Caroline F Morrison; Donna M Martsolf; Nicole Wehrkamp; Rebecca Tehan; Ahna L H Pai Journal: Biol Blood Marrow Transplant Date: 2017-01-10 Impact factor: 5.742
Authors: Sylvie D Lambert; Lydia Ould Brahim; Marjorie Morrison; Afaf Girgis; Mark Yaffe; Eric Belzile; Karissa Clayberg; John Robinson; Sally Thorne; Joan L Bottorff; Wendy Duggleby; Heather Campbell-Enns; Youngmee Kim; Carmen G Loiselle Journal: Support Care Cancer Date: 2018-07-31 Impact factor: 3.603
Authors: Avani C Modi; Ahna L Pai; Kevin A Hommel; Korey K Hood; Sandra Cortina; Marisa E Hilliard; Shanna M Guilfoyle; Wendy N Gray; Dennis Drotar Journal: Pediatrics Date: 2012-01-04 Impact factor: 7.124
Authors: Ahna L H Pai; Avi Madan Swain; Fang Fang Chen; Wei-Ting Hwang; Gabriela Vega; Olivia Carlson; Francisco Argueta Ortiz; Kimberly Canter; Naomi Joffe; E Anders Kolb; Stella M Davies; Joseph H Chewning; Janet Deatrick; Anne E Kazak Journal: Biol Blood Marrow Transplant Date: 2019-03-14 Impact factor: 5.742
Authors: Ahna L H Pai; Joseph Rausch; Sarah Drake; Caroline F Morrison; Jennifer L Lee; Adam Nelson; Alayna Tackett; Suzanne Berger; Lauren Szulczewski; Constance Mara; Stella Davies Journal: Biol Blood Marrow Transplant Date: 2017-11-02 Impact factor: 5.742
Authors: Charles D Varnell; Kristin L Rich; Bin Zhang; Adam C Carle; Ahna L H Pai; Avani C Modi; David K Hooper Journal: Pediatr Nephrol Date: 2021-01-27 Impact factor: 3.651